FDA fast-tracks psychedelic drug research following Trump executive order
Summary
It's a big shift toward supporting psychedelic-based medicines for treatment-resistant depression, PTSD and substance use disorders, the FDA said.
Description
It's a big shift toward supporting psychedelic-based medicines for treatment-resistant depression, PTSD and substance use disorders, the FDA said.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source